Human papillomavirus (HPV) types 16/18 are common sexually transmitted viruses that are classified as high-risk (HR-HPV) because persistent infections are associated with ano-genital and other cancers including the head and neck (Bouvard et al, 2009). Two vaccines against HPV16/18 infection are now widely used. The bivalent vaccine (Cervarix) protects against HPV16/18.
The quadrivalent vaccine (Gardasil) protects against HPV16/18 and the low-risk types HPV6/11 which are responsible for the majority of genital warts (Schiller et al, 2012). A nonavalent vaccine targeting five additional HR-HPV types, 31, 33, 45, 52, 58 (Bouvard et al, 2009), responsible for a further 20% of cervical cancers (Muñoz et al, 2005; De Sanjose et al, 2010), is expected to be licensed (Joura et al, 2014; Olsson et al, 2014). In 2008, the UK introduced an HPV immunisation programme for adolescent girls, primarily as protection from cervical cancer (Jit et al, 2008; Department of Health, United Kingdom Government, 2014). With over 80% coverage among young girls, herd immunity is expected to reduce HPV infection and associated disease in unvaccinated females and heterosexual males, as has been observed in Australia and Sweden (Leval et al, 2012; Ali et al, 2013). Provided vaccine coverage was high, including boys in the UK programme was considered not cost-effective, but this is being reconsidered (Jit et al, 2008). Men who have sex with men (MSM) are unlikely to benefit from herd immunity with the current programme (Ali et al, 2013), are more likely to be infected with HPV (Nyitray et al, 2011) and have relatively high rates of HPV-related disease, particularly genital warts (Anic et al, 2012) and anal cancer (Frisch et al, 2003). Anal cancer incidence is increasing and is estimated at 1, 5 and 46/100,000 person years in all men, HIV-negative MSM and HIV-positive MSM, respectively (Frisch et al, 2003; Wilkinson et al, 2014).

Quadrivalent vaccine trials show efficacy against anal intraepithelial neoplasia (AIN) in men. In participants with no evidence of prior infection receiving three doses, vaccination was 78% (95% CI 40–93) efficacious against HPV 6/11/16/18-related AIN and 95% (95% CI 80–99) against persistent anal HPV infection (6/11/16/18) in 16–26 year old men (Palesfky et al, 2011), and 90% (95% CI 69–98) efficacious against 6/11/16/18-related external genital lesions (principally genital warts; Giuliano et al, 2011b). In the intention-to-treat analyses, including those with prior HPV infection, efficacy was lower, but still substantial, at 50% (95% CI 26–67) against AIN and 66% (95% CI 41–74) against genital warts. Given the efficacy against cervical, vulval, vaginal and now anal disease, it is expected that vaccines will protect against other HPV16/18-related cancers for example penile and oropharyngeal. Vaccination may also benefit previously exposed individuals (Swedish et al, 2012; Swedish and Goldstone, 2014).

Prevalence of HPV DNA in genital specimens does not measure cumulative exposure as 70% of genital high-risk HPV (HR-HPV) infections in men clear by 12 months (Giuliano et al, 2011a). Nevertheless, age-specific DNA prevalence, linked to behavioural data, gives valuable insights into the epidemiology of HPV. A systematic review of HPV in MSM reported a pooled anal data, gives valuable insights into the epidemiology of HPV. Nevertheless, age-specific DNA prevalence, linked to behavioural data, gives valuable insights into the epidemiology of HPV. A systematic review of HPV in MSM reported a pooled anal data, gives valuable insights into the epidemiology of HPV.

Recruitment and study procedures. Men attending the MMC, who reported anal or oral sex with another man in the last five years, aged 16–40 years inclusive, were consented to participate in this cross-sectional study. With an estimate for HPV prevalence of 16%, a sample size of 530 men would provide 80% power to detect a difference between two equally sized subgroups (e.g., age groups) at the 5% significance level if the true prevalence in the subgroups is 12% and 21%, that is, a relative risk of 1.75.

Participants completed a computer-assisted self-interview (CASI) questionnaire covering demographics, sexual behaviour, history of sexually transmitted infections (including HIV), knowledge of HPV, attitudes to HPV vaccination and health service use. Specimens were collected as follows: an anal specimen was obtained by inserting a sterile plastic flocked swab that was pre-soaked in sterile saline 3 cm into the anal canal and rotated 360 degrees; an external genital specimen was obtained by rubbing a similar swab on the glans penis/coronal sulcus, penile shaft including the prepuce (if present), scrotum, and perianal area; a first-void urine specimen was collected into a 30 ml universal collection tube. Swabs were placed in UTM-RT medium (Copan Diagnostics, Murrieta, CA, USA). Specimens were stored immediately at 4 °C and transferred in cold condition to the laboratory within 24 h.

STI diagnoses within 30 days of the study visit and HIV test history were recorded (Health protection Agency, 2014).

Laboratory methods. In the laboratory, swab specimens were vortexed to agitate the material from the swab into the buffer and aliquots of 300 μl were stored at −80 °C. Urine specimens (1 ml) were centrifuged (13,000 r.p.m. for 20 min) and the pellet was resuspended in 300 μl sterile phosphate-buffered saline prior to storage at −80 °C. Specimens were removed for batch processing wherein all available specimens from each individual were processed for DNA extraction and HPV testing in the same run. Following lysis with 40 μl Qiagen Protease and 265 μl Qiagen buffer, nucleic acid was extracted on a BioRobot Universal platform using QIAampDNA Blood BioRobot MDx kit (Qiagen, Crawley, West Sussex, UK). Ten microlitres of the 100 μl elution were used for PCR amplification using the in-house single-round multiplex PCR and type-specific infections were resolved using a genotyping assay based on the Bio-Plex (Luminex xMAP, Bio-Rad Laboratories, Hemel Hempstead, Hertfordshire, UK) platform (Bissett et al, 2011). Specimen integrity was established by incorporating a control PCR targeting the human pyruvate-dehydrogenase gene. HPV genotypes 16/18/31/33/35/39/45/51/ 52/56/58/59/68 were considered as HR-HPV types, HPV genotypes 6/11 were considered as low-risk HPV (LR-HPV) types whereas HPV genotypes 26/53/66/70/73/82 were considered as possible HR-HPV (Bouvard et al, 2009).
Statistical methods. Human papillomavirus DNA prevalence was defined as the proportion of participants with detectable HPV DNA in ≥1 of the three specimen types in participants with ≥1 specimen type that was adequate for PCR. We estimated HPV DNA prevalence by HPV type, HIV status, specimen type and age. Confidence intervals (95%) were determined by the Clopper–Pearson (exact) method. Human immunodeficiency virus status was determined from both questionnaire data (self-reported) and clinical records at MMC.

We used univariate logistic regression to explore the age-relationship with HPV infection (any type, HPV16/18, any quadrivalent vaccine types, any nonavalent vaccine types, any HR-HPV, and HPV6/11). To explore the potential for future HPV acquisition at any age, we examined the effect of age on sexual behaviour using linear regression. Demographic and behavioural risk factors for quadrivalent vaccine types were assessed using logistic regression and we present age-adjusted odds ratios (aOR) with 95% confidence intervals. Health service use, HPV knowledge and STI risk perception, by quadrivalent HPV type status, were explored to identify potential opportunities and barriers for delivery of vaccination. Statistical analyses were conducted using STATA v13.1 (StataCorp LP, College Station, TX, USA).

Ethical review. The study was reviewed by the Camden and Islington Research ethics committee (REC reference number: 09/H0722/71) and received NHS approval (R&D ref: CSP 30296).

RESULTS

Participation and response. A total of 522 MSM were recruited between October 2010 and July 2012. The participation rate was estimated at 81.4% from the enrolment log. All analyses were restricted to the 511 participants (97.9%) that had ≥1 specimen type that was valid for PCR. Of these, 495 completed a CASI form.

Participant characteristics. Table 1 shows demographic and behavioural characteristics of study participants. The median age was 30 years (IQR 25–35), with 17 participants (3.3%) younger than 21 years. Nearly half (46.9%) were born in the UK and another 38.4% had lived in the UK for at least 3 years. The majority (76.2%) were of white ethnicity. Overall 91.5% self-identified as gay/homosexual. Most participants were employed (78.8%), with ≥3 years of education post-16 (68.7%). Two-thirds (65.9%) reported higher risk drinking behaviour (identified using the alcohol use disorders identification test; AUDIT-C) and one-third (29.4%) were current smokers. A total of 28.9% were circumcised and 27 participants (5.3%) had been diagnosed as HIV-positive and 28 (5.7%) had never had an HIV test.

The study population broadly mirrors that of MSM attending MMC in terms of age and ethnicity, but were slightly younger (data not shown). Men who have sex with men attending other SHGs in England are younger and less ethnically diverse (Public Health England, personal communication).

Human papillomavirus prevalence. The prevalence of HPV at any site was 72.2% (95% CI 68.2–75.9) (Table 2). The prevalence of HR-HPV types was 47.2% (95% CI 42.9–51.5). The most common HPV types were 16, 11 and 6 with prevalence estimates of 13.5% (95% CI 10.8–16.8), 11.5% (95% CI 9.0–14.6) and 9.4% (95% CI 7.1–12.3), respectively. At least one quadrivalent vaccine type was detected in 32.5% of participants; 18.4% (95% CI 15.3–22.0) had a bivalent type(s); 18.6% (95% CI 15.4–22.2) had types 6 and/or 11. The 27 HIV-POSITIVE MSM had a higher HPV prevalence (92.6%; 95% CI 75.7–99.1) compared with the 484 HIV-negative MSM (71.1%; 95% CI 66.8–75.1). Similarly, HIV-positive MSM had higher prevalence of quadrivalent (59.3% (38.8–77.6) vs 31.0% (26.9–35.3)) and nonavalent (74.1% (53.7–88.9) vs 43.8% (39.3–48.4)) vaccine types.

Table 3 shows the prevalence of vaccine-preventable HPV types by specimen type. A total of 132 men (29.1%) had at least one detectable quadrivalent type in the anal canal. A further 28 men

| Table 1. Demographic and behavioural characteristics of 511 participants |
|----------------------------------------|--------|
| Age group (years) | n* | Percentage |
| 18–20 | 17 | 3.3 |
| 21–25 | 119 | 23.3 |
| 26–30 | 127 | 24.9 |
| 31–35 | 140 | 27.4 |
| 36–40 | 108 | 21.1 |

| Ethnicity | n* | Percentage |
|-----------|----|------------|
| White | 377 | 76.2 |
| Black | 30 | 6.1 |
| Asian and SE Asian | 34 | 6.9 |
| Mixed/Other | 51 | 10.3 |

| Born in the United Kingdom | n* | Percentage |
|---------------------------|----|------------|
| No | 263 | 51.3 |
| Yes | 232 | 46.9 |

| Sexual orientation | n* | Percentage |
|-------------------|----|------------|
| Gay/homosexual | 452 | 91.5 |
| Bisexual | 42 | 8.5 |

| Currently employed | n* | Percentage |
|--------------------|----|------------|
| No | 105 | 21.2 |
| Yes | 390 | 78.8 |

| Years of education since the age of 16 years | n* | Percentage |
|---------------------------------------------|----|------------|
| None | 13 | 2.6 |
| Up to 2 years | 58 | 11.7 |
| 3 years or more | 340 | 68.7 |
| Still in education | 84 | 17.0 |

| Circumcised | n* | Percentage |
|-------------|----|------------|
| No | 349 | 71.1 |
| Yes | 142 | 28.9 |

| Alcohol use disorders identification test—AUDIT-C | n* | Percentage |
|-----------------------------------------------|----|------------|
| No-risk drinking | 167 | 34.2 |
| Risk drinking | 322 | 65.9 |

| Currently smokes cigarettes | n* | Percentage |
|-------------------------------|----|------------|
| No | 349 | 70.7 |
| Yes | 145 | 29.4 |

| Age at first receptive anal sex | n* | Percentage |
|-------------------------------|----|------------|
| Up to 15 years | 34 | 7.5 |
| 16–20 years | 232 | 51.2 |
| 21–25 years | 140 | 30.9 |
| 26–39 years | 47 | 10.4 |

| Total lifetime male partners oral and anal | n* | Percentage |
|-------------------------------------------|----|------------|
| ≤20 | 94 | 19.0 |
| 21–30 | 73 | 14.9 |
| 31–100 | 168 | 34.0 |
| 101–500 | 159 | 32.2 |

| Number of anal sex partners without a condom in the last year (if had anal sex in last year) | n* | Percentage |
|------------------------------------------------------------------------------------------|----|------------|
| No partners without a condom | 173 | 37.4 |
| 1 | 124 | 26.8 |
| 2–4 | 104 | 22.5 |
| 5–10 | 40 | 8.6 |
| 11–30 | 15 | 3.2 |
| >30 | 17 | 3.5 |

| Diagnosed as HIV positive | n* | Percentage |
|---------------------------|----|------------|
| No | 484 | 94.7 |
| Yes | 27 | 5.3 |

*Total numbers vary for each question because of missing items.
anal any infection per year. The effect was not significant when examining
18–40 years. There was a 4.7% (95% CI 1.2–8.4) increase in the odds of an HPV
type, and modelling age as a continuous variable (18–40 years),
swabs. these infections were in addition to the 160 detected in the two
men (3.3%) had detectable quadrivalent types in their urine, 6 of
the prevalence in these two samples was 32.1%. Although only 16
had quadrivalent types detected in the external genital swab so that
it is possible for the total to be greater than the sum of its parts.
Table 2. Type-specific prevalence of HPV DNA in any
specimen type (n=511)\(^a\)

| HPV type                             | Percentage of participants with at least one adequate sample (95% CI) |
|--------------------------------------|---------------------------------------------------------------|
| Any HPV type\(^b\)                     | 72.2 (68.1–76.1)                                              |
| Multiple types (2 or more)            | 29.2 (25.3–33.3)                                              |
| Multiple HR types\(^a\) (2 or more)    | 17.4 (14.2–21.0)                                              |
| Any quadrivalent vaccine types (6/11/16/18) | 32.5 (28.6–36.7)                                              |
| Any nonavalent vaccine types (6/11/16/18/31/33/45/52/58) | 45.4 (41.0–49.8)                                              |
| HR-HPV\(^c\)                          | 47.2 (42.8–51.6)                                              |
| 16 and/or 18                          | 18.4 (15.1–22.0)                                              |
| 16                                    | 13.5 (10.7–16.8)                                              |
| 18                                    | 6.3 (4.3–8.7)                                                 |
| 31                                    | 1.6 (0.7–3.1)                                                 |
| 33                                    | 2.5 (1.4–4.3)                                                 |
| 35                                    | 3.3 (1.9–5.3)                                                 |
| 39                                    | 5.9 (4.0–8.3)                                                 |
| 45                                    | 9.0 (6.7–11.8)                                                |
| 51                                    | 4.7 (3.0–6.9)                                                 |
| 52                                    | 7.8 (5.7–10.5)                                                |
| 56                                    | 5.5 (3.7–7.8)                                                 |
| 58                                    | 2.3 (1.2–4.1)                                                 |
| 59                                    | 1.0 (0.3–2.3)                                                 |
| 68                                    | 7.8 (5.7–10.5)                                                |
| Possibly HR-HPV                       | 14.1 (11.3–17.4)                                              |
| 26                                    | 1.6 (0.7–3.1)                                                 |
| 53                                    | 5.7 (3.8–8.0)                                                 |
| 66                                    | 0.6 (0.1–1.7)                                                 |
| 70                                    | 2.7 (1.5–4.6)                                                 |
| 73                                    | 4.9 (3.2–7.1)                                                 |
| 82                                    | 0.0 (0.0–0.7)                                                 |
| Low-risk HPV types                    |                                                              |
| 6 and/or 11                           | 18.6 (15.3–22.2)                                              |
| 6                                     | 9.4 (7.0–12.3)                                                |
| 11                                    | 11.5 (8.9–14.6)                                               |

Abbreviations: CI = confidence interval; HPV = human papillomavirus; HR = high risk; HR-HPV = high-risk HPV types; MSM = men who have sex with men.
\(^a\)Total of 27/511 were HPV-positive MSM in whom: 25 had detectable HPV, 16 multiple types, 11 multiple HR types, 16 of any quadrivalent types, 20 of any nonavalent types, 20 of HR-HPV types, 10 of HPV16/18 types and 8 of HPV6/11 types.
\(^b\)HR-HPV detected at anus (via swab) or external genitalia including penis (via swab) or urine. If any of the 3 sample types were adequate for DNA detection then included in the denominator.
\(^c\)HR-HPV classified according to IARC monograph carcinogenic or probably carcinogenic.

had quadrivalent types detected in the external genital swab so that
the prevalence in these two samples was 32.1%. Although only 16
men (3.3%) had detectable quadrivalent types in their urine, 6 of
these infections were in addition to the 160 detected in the two
swabs.

Figure 1 shows age-specific prevalence of HPV. For any HPV
type, and modelling age as a continuous variable (18–40 years),
there was a 4.7% (95% CI 1.2–8.4) increase in the odds of an HPV
infection per year. The effect was not significant when examining

age as a categorical variable, but confidence intervals are wide, and
there were few participants in the youngest category in particular
(18–20 years). There was no significant association between age
and HR-HPV, bivalent, quadrivalent or nonavalent vaccine-type
detection, considered separately. There was a 2.5% increase in the
odds of acquiring a HR-HPV infection per year between the ages of
18 and 40, although this was not statistically significant (P = 0.12).
The increase was 7.0% per year (95% CI = 0.2–17.3) from 21 to 30
years (P = 0.14) and then decreased by 2.3% per year between 31
and 40 (P = 0.61).

Sexual behaviour. The majority of men (51.2%) reported first
receptive anal sex between 16–20 years old (Table 1). The median
age at first oral, insertive anal and receptive anal sex with a man was 18 (IQR 16–20), 19 (IQR 17–22) and 19 (IQR 17–23), respectively. Two-thirds of men (66.2%) had had > 30 lifetime male-sex (anal or oral) partners and only six men (1.2%) had fewer than three lifetime partners. Of those who had an anal sex partner in the last year, 62.6% had sex with at least one partner without a condom. For each year increase in age, the odds of having > 30 lifetime partners increased by 14.1% (95% CI 10.0–18.4) but there was no association between age and the number of partners, new partners or partners without a condom in a year. For example, the median number of male anal partners in the last year was 6 (IQR 3–15) in men aged 18–30 and 8 (IQR 3–20) in men aged 31–40. Younger men, aged 18–30, were more likely to have had receptive anal sex in the last year than older men (86% vs 77%; OR 1.8; 95% CI 1.1–2.9). The proportion of men who had sex without a condom in the last year was higher among younger men, (66% vs 58%; OR 1.4 95% CI 0.9–2.0) but this was not statistically significant.

Participants had more lifetime partners than MSM who had attended a SHC (in the last five years) in the British population in 2010–2012 measured in the Natsal-3 population-based survey. Within Natsal-3, MSM who had attended a SHC had more lifetime partners than those who had not. For example, 93% of MSM in our study reported > 10 lifetime partners, compared with the 78% of MSM who had attended a SHC in Natsal-3 and with the 25% of MSM who had not attended. (Natsal-3 team, personal communication)

**Risk factors for quadrivalent vaccine-type infection.** Detection of any quadrivalent vaccine types was associated with number of lifetime anal or oral sex partners (aOR 2.6; 95% CI 1.4–4.8; in those with >100 compared with ≤20 partners), an HIV-positive diagnosis (aOR 3.2; 95% CI 1.5–7.1) and rectal drug use (aOR 2.0; 95% CI 1.1–3.6) (Supplementary Table 1). There were no other statistically significant associations between quadrivalent type infection and demographic, health or behavioural variables, after adjusting for age.

**Health-seeking behaviour, HPV knowledge and risk perception.** The median age at first attending a SHC in the United Kingdom was 24 (IQR 20–27) (Table 4); 77% had visited their GP in the last year but only 44% of these had disclosed their sexuality; 88% had received at least one dose of hepatitis-B vaccine of whom 47% had received ≥3 doses. Only 4% of the MSM reported that they would probably or definitely refuse the HPV vaccine if it was offered. There were no significant differences in health-seeking behaviour, HPV knowledge, STI risk perception or expected vaccine acceptance between those who had quadrivalent vaccine types detected and those who did not.

**DISCUSSION**

This study, in over 500 MSM attending a London SHC, found that two-thirds (67.5%) of men did not have any of the quadrivalent vaccine-types detectable. A quarter (25.1%) had one type, 7.4% had two or three types and none had all four quadrivalent types detected. Our results are similar to those reported in a recent systematic review of anal canal HPV prevalence in MSM (Machalek et al, 2012). On the basis of the evidence of current infection, there is a potential benefit in vaccinating this group of men, which would be increased if the vaccine is also effective in those with previous exposure (Swedish et al, 2012; Swedish and Goldstone, 2014). These data can inform decisions on vaccination strategies for MSM, and mathematical models of effectiveness and cost-effectiveness.

The results suggest that extending from quadrivalent vaccine to the nonavalent vaccine could protect a further 13–22% of participants from HR-HPV infection. It is not clear how this translates into potentially preventable HPV-related disease. In men, it is estimated that quadrivalent vaccine could prevent up to 76% of anal cancers and 88% in women (Hoots et al, 2009). A further 7% of male anal cancers might be prevented with the nonavalent vaccine (Hoots et al, 2009).

As the MSM in our study are, on average, at higher risk, in terms of STI acquisition, than MSM generally in the United Kingdom, we will have underestimated the proportion of MSM who may benefit from vaccination.

Vaccine effectiveness is highest in HPV-naive individuals (Palefsky et al, 2011). Human papillomavirus DNA testing is a marker of current infection and gives no information on previous resolved episodes. The majority of HPV infections are transient, and the median time to clearance of genital HR-HPV is estimated to be 7.2 months (Giuliano et al, 2011a). Detecting HPV antibodies in serum may provide evidence of previous exposure, but lacks
sensitivity owing to low seroconversion rates (Carter et al., 2000; Edelstein et al., 2011; Giuliano, 2014).

Men who have sex with men in our study reported attending a SHC for the first time at the age of 24, an average of five years after the initiation of anal sex. One in three MSM aged 18–23 years had detectable quadrivalent vaccine-type DNA. We estimate that, if 33% of MSM are infected at an age of 19 years (and those negative are all naive to the quadrivalent types), and prevalence remains at 33%, all men will have been infected by the age of 24.5 years with an incidence of 0.9%/month, if the average duration of infection is seven months and there is no natural immunity.

Human immunodeficiency virus-negative MSM in Thailand had a 12-month cumulative incidence of 7.2% (95% CI 3.0–17.5%) and 33.9% (21.1–54.5%) for HPV16 and HR-HPV, respectively (Phanuphak et al., 2013). Thus it is unlikely that MSM will be completely HPV-naive for vaccine-preventable types by the time they first attend a SHC. That said, vaccine efficacy in MSM who are not HPV-naive has been demonstrated. In older MSM (≥26 years), including MSM with a history of HPV infection, the quadrivalent vaccine was 55% (95% CI 8–78%) efficacious against anal warts after five years (Swedish and Goldstone, 2014); and in MSM (mean age 40), with a history of biopsy-confirmed and treated high-grade AIN (HGAIN; a precursor to anal cancer), it was 50% (95% CI 2–74%) efficacious against recurrent HGAIN.

Table 4. Health service use, HPV knowledge, risk perception and vaccine acceptance in MSM with and without any detectable quadrivalent vaccine types

| Age at first attendance at UK SHC (years) | Total | Quadrivalent vaccine type(s) not detected | Quadrivalent vaccine type(s) detected | Age-adjusted OR | 95% CI | P-value |
|------------------------------------------|-------|------------------------------------------|--------------------------------------|-----------------|-------|---------|
| 15–18| 47 | 14.0 | 29 | 13.0 | 18 | 16.1 | 1 | — | 0.92 |
| 19–24 | 150 | 44.6 | 101 | 45.1 | 49 | 43.8 | 0.79 | (0.39–1.59) |
| 25–29 | 97 | 28.9 | 66 | 29.5 | 31 | 27.7 | 0.78 | (0.34–1.81) |
| 30–25 | 42 | 12.5 | 28 | 12.5 | 14 | 12.5 | 0.84 | (0.30–2.34) |

| Visited GP in last year | Total | Quadrivalent vaccine type(s) not detected | Quadrivalent vaccine type(s) detected | Age-adjusted OR | 95% CI | P-value |
|-------------------------|-------|------------------------------------------|--------------------------------------|-----------------|-------|---------|
| No | 85 | 17.2 | 60 | 18.0 | 25 | 15.6 | 1 | — | 0.82 |
| Yes | 381 | 77.1 | 255 | 76.4 | 126 | 78.8 | 1.18 | (0.71–1.98) |
| Not registered with GP | 28 | 5.7 | 19 | 5.7 | 9 | 5.6 | 1.13 | (0.45–2.84) |

| Told GP sexuality | Total | Quadrivalent vaccine type(s) not detected | Quadrivalent vaccine type(s) detected | Age-adjusted OR | 95% CI | P-value |
|-------------------|-------|------------------------------------------|--------------------------------------|-----------------|-------|---------|
| No | 285 | 61.2 | 191 | 60.6 | 94 | 62.3 | 1 | — | 0.74 |
| Yes | 181 | 38.8 | 124 | 39.4 | 57 | 37.8 | 0.93 | (0.63–1.39) |

| Ever had HIV test | Total | Quadrivalent vaccine type(s) not detected | Quadrivalent vaccine type(s) detected | Age-adjusted OR | 95% CI | P-value |
|-------------------|-------|------------------------------------------|--------------------------------------|-----------------|-------|---------|
| No | 28 | 5.7 | 20 | 6.0 | 8 | 5.0 | 1 | — | 0.70 |
| Yes | 466 | 94.3 | 314 | 94.0 | 152 | 95.0 | 1.18 | (0.51–2.76) |

| Most recent test | Total | Quadrivalent vaccine type(s) not detected | Quadrivalent vaccine type(s) detected | Age-adjusted OR | 95% CI | P-value |
|------------------|-------|------------------------------------------|--------------------------------------|-----------------|-------|---------|
| In the last 12 months | 360 | 78.6 | 241 | 78.3 | 119 | 79.3 | 1 | — | 0.77 |
| >1 year ago | 98 | 21.4 | 67 | 21.8 | 31 | 20.7 | 0.93 | (0.58–1.51) |

| Knowledge about HPV | Total | Quadrivalent vaccine type(s) not detected | Quadrivalent vaccine type(s) detected | Age-adjusted OR | 95% CI | P-value |
|---------------------|-------|------------------------------------------|--------------------------------------|-----------------|-------|---------|
| 0–4 correct answers | 218 | 45.5 | 148 | 45.7 | 70 | 45.2 | 1 | — | 0.89 |
| 5–9 correct answers | 261 | 54.5 | 176 | 54.3 | 85 | 54.8 | 1.03 | (0.70–1.51) |

| STI risk perception-compared with other people same age | Total | Quadrivalent vaccine type(s) not detected | Quadrivalent vaccine type(s) detected | Age-adjusted OR | 95% CI | P-value |
|--------------------------------------------------------|-------|------------------------------------------|--------------------------------------|-----------------|-------|---------|
| Much below average | 19 | 3.9 | 14 | 4.2 | 5 | 3.1 | 1 | — | 0.16 |
| Below average | 66 | 13.4 | 53 | 15.9 | 13 | 8.2 | 0.68 | (0.21–2.23) |
| Average | 193 | 39.2 | 128 | 38.3 | 65 | 40.9 | 1.42 | (0.49–4.12) |
| Above average | 173 | 35.1 | 114 | 34.1 | 59 | 37.1 | 1.44 | (0.49–4.18) |
| Much above average | 42 | 8.5 | 25 | 7.5 | 17 | 10.7 | 1.89 | (0.57–6.23) |

| STI risk perception-compared with other MSM same age | Total | Quadrivalent vaccine type(s) not detected | Quadrivalent vaccine type(s) detected | Age-adjusted OR | 95% CI | P-value |
|-----------------------------------------------------|-------|------------------------------------------|--------------------------------------|-----------------|-------|---------|
| Much below average | 34 | 7.0 | 26 | 7.9 | 8 | 5.2 | 1 | — | 0.57 |
| Below average | 119 | 24.5 | 83 | 25.2 | 36 | 23.2 | 1.40 | (0.58–3.39) |
| Average | 232 | 47.8 | 159 | 48.2 | 73 | 47.1 | 1.48 | (0.64–3.43) |
| Above average | 75 | 15.5 | 46 | 13.9 | 29 | 18.7 | 2.02 | (0.81–5.08) |
| Much above average | 25 | 5.2 | 16 | 4.9 | 9 | 5.8 | 1.84 | (0.59–5.75) |

| Ever had hepatitis-B virus vaccine | Total | Quadrivalent vaccine type(s) not detected | Quadrivalent vaccine type(s) detected | Age-adjusted OR | 95% CI | P-value |
|-----------------------------------|-------|------------------------------------------|--------------------------------------|-----------------|-------|---------|
| No | 63 | 12.8 | 47 | 14.1 | 16 | 10.1 | 1 | — | 0.23 |
| Yes | 430 | 87.2 | 287 | 85.9 | 143 | 89.9 | 1.46 | (0.80–2.67) |

| Self-perceived likelihood of accepting the 3-dose HPV vaccine | Total | Quadrivalent vaccine type(s) not detected | Quadrivalent vaccine type(s) detected | Age-adjusted OR | 95% CI | P-value |
|-------------------------------------------------------------|-------|------------------------------------------|--------------------------------------|-----------------|-------|---------|
| Definitely | 288 | 58.3 | 186 | 55.7 | 102 | 63.8 | 1 | — | 0.40 |
| Probably | 124 | 25.1 | 87 | 26.1 | 37 | 23.1 | 0.78 | (0.49–1.23) |
| Possibly | 62 | 12.6 | 47 | 14.1 | 15 | 9.4 | 0.58 | (0.31–1.10) |
| Probably not | 14 | 2.8 | 9 | 2.7 | 5 | 3.1 | 1.01 | (0.33–3.10) |
| Definitely not | 6 | 1.2 | 5 | 1.5 | 1 | 0.6 | 0.37 | (0.04–3.17) |

Abbreviations: CI = confidence interval; GP = general practitioner; HIV = human immunodeficiency virus; HPV = human papillomavirus; MSM = men who have sex with men; SHC = sexual health clinic.

*Total numbers vary for each question because of missing items: survey questions that were not asked (because of routing) or not answered. Total including the missing items is 495. 

1590 www.bjcancer.com | DOI:10.1038/bjc.2015.90
after 2 years (Swedish et al, 2012). Furthermore, cost-effectiveness, taking into account indirect benefits, is not reliant on HPV-naïvetry in the whole population (Kim, 2010; Zou et al, 2014).

In our MSM population, aged 18–40 years, rates of partner change and prevalence of HPV did not decline with age and there was no association between detectable quadrivalent vaccine types and age at first sex. We found that the prevalence of any HPV infection increased with age but no significant associations were detectable when individual or grouped LR-HPV or HR-HPV were considered. The MSM in this study reported high levels of sexual risk behaviour. Therefore the risk of future infection with HPV is likely to be high across all age groups as demonstrated by comparing HPV prevalence in MSM populations with different age distributions (Zou et al, 2014). The rapidly diminishing benefit of vaccination with age seen in women, as a result of the age-association with cervical HPV infection, may not apply to MSM.

Our high estimates for ano-genital HPV prevalence in HIV-positive MSM are similar to those in larger European HIV-positive MSM populations (Parisi et al, 2011; Videla et al, 2013). Human immunodeficiency virus-positive MSM have more preventable HPV infection, and HPV vaccines have been shown to be safe and highly immunogenic in HIV-positive populations (Toft et al, 2014), so vaccination of HIV-positive MSM has great potential and cost-effectiveness analyses should stratify by HIV status.

Although the number in each age stratum was limited, our data suggest that HR-HPV prevalence increases until the approximate age of 30 years. This is consistent with the results from the largest HPV study (EXPLORE), in HIV-negative MSM in the United States of America (n = 1409; median age 37; IQR 31–43), which found no overall association with age (any type, LR-HPV or HR-HPV) but did show an increase in HR-HPV through the age-bands from <25 years until 30–34 years (Chin-Hong et al, 2004). After the age of 30 years, HR-HPV prevalence may slowly decline with age as was shown in the EXPLORE study (Chin-Hong et al, 2004) and the HIM study (for both any HPV and HR-HPV (Nyttrey et al, 2011)). We found a non-significant decrease of HR-HPV with age between 31 and 40 years. The lack of age-association across the entire age range in EXPLORE could be because 78% were 30 years or older (Chin-Hong et al, 2004).

This is the first study to estimate the prevalence of all HPV genotypes included in the bivalent, quadrivalent and nonavalent vaccines, with sampling at multiple genital sites, in a predominantly HIV-negative population of MSM attending a SHC. It is the first large study of HPV prevalence in MSM in the United Kingdom, recruited from a large SHC in London. This study has some limitations including that not all men were tested for HIV at the clinic visit so there is a potential for undiagnosed HIV. This potential misclassification would overestimate the HPV prevalence in HIV-negative MSM. The sensitivity for the detection of HPV DNA in urine is lower than genital swabs (Pathak et al, 2014) and we observed a low HPV prevalence in this specimen type. Despite low prevalence, we did identify HPV DNA in the urine of some participants when it had not been detected in other specimens, differences in HPV test sensitivity/specificity and specimen quality across specimen types may contribute to non-concordance.

Sexual health clinics provide an opportunity to vaccinate MSM, a group at high risk of HPV infection, who do not readily identify themselves to GPs. Forty-five percent of MSM in a national survey in Britain between 2010–2012 had attended a SHC in the last five years (Sonnenberg et al, 2013). The HPV prevalence and sexual activity levels that we report show that vaccinating MSM attending SHCs who have the highest STI transmission risk behaviours would undoubtedly incur a lower vaccine efficacy than vaccinating all MSM (however that might be achieved) or all adolescent males. However, the indirect benefits for other MSM, who are not attending SHCs, may be substantial given the current high infection rates, and help to compensate for the reduction in efficacy. Even if a country such as the United Kingdom were to include all adolescent boys in a routine vaccination programme, there would be potential benefit in vaccinating MSM for some years as a catch-up programme.

In this study of MSM with high numbers of lifetime partners, no participant had all four vaccine-preventable HPV types detected in their genital specimens. Many are likely to have encountered and resolved infections prior to the study. As vaccine effectiveness has been demonstrated in older HPV-exposed MSM, and there appears to be a continuing risk of acquiring new HPV infections, there is potential benefit in vaccinating this group, at least with the quadrivalent vaccine. The nonavalent vaccine would provide additional protection, but the benefit in disease prevention would need to be assessed further. The results reported here are necessary to inform models that quantify the impact and cost-effectiveness of HPV vaccination strategies.

ACKNOWLEDGEMENTS

We thank Natsal-3 for providing estimates for sexual behaviour in MSM, Cath Mercer for advice on questionnaire design, Andrew Copas for statistical advice, Graham Hart for advice during study planning, David Mesher for providing data from the Genitourinary Medicine Clinic Activity Dataset (GUMCAD) at Public Health England, which provided demographic estimates for MSM at STI clinics. WJE’s partner works for GSK. EMK was funded on a Medical Research Council (MRC) studentship. The study was supported in part by funds from the National Institute of Health Research (NIHR). There was no commercial funding.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

Van Aar F, Mooij SH, van der Sande MAB, AGCL S, Stolte IG, M CJLM, Verhagen DWM, King AJ, de Vries HJC, Schim van der Loeff MF (2013) Anal and penile high-risk human papillomavirus prevalence in HIV-negative and HIV-infected MSM. AIDS 27: 2921–2931.

Ali H, Donovan B, Wand H, Read TRH, Regan DG, Gruelich AE, Fairley CK, Guy RJ (2013) Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 346: e2032.

Anic GM, Lee J-H, Villa LL, Lazcano-Ponce E, Gage C, José C, Sávila R, Baglio ML, Quiterio M, Salmerón J, Papenfuss MR, Abrahamsen M, Stockwell H, Rollison DE, Wu Y, Giuliano AR (2012) Risk factors for incident condyloma in a multinational cohort of men: the HIM study. J Infect Dis 205: 789–793.

Bissett SL, Howell-Jones R, Swift C, De Silva N, Biscornet L, Parry JV, Saunders NA, Nathan M, Soldan K, Szarewski A, Cuzick J, Beddows S (2011) Human papillomavirus genotype detection and viral load in paired genital and urine samples from both females and males. J Med Virol 83: 1744–1751.

Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Coglian V, WHO International Agency for Research on Cancer Monograph Working Group (2009) A review of human carcinogens–Part B: biological agents. Lancet Oncol 10: 321–322.

Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kiviat N, Galloway DA (2000) Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 181:1911–1919.

Chin-Hong PV, Vittinghoff E, Cranston RD, Buchbinder S, Cohen D, Colfax G, Da Costa M, Darragh T, Hess E, Judson F, Koblin B, Madison M, Palefsky JM (2004) Age-specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study. J Infect Dis 190: 2070–2076.
Zou H, Tabrizi SN, Grulich AE, Garland SM, Hocking JS, Bradshaw CS, Morrow A, Prestage G, Cornall AM, Fairley CK, Chen MY (2014) Early acquisition of anogenital human papillomavirus among teenage men who have sex with men. *J Infect Dis* **209**: 642–651.

Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)